Startup profile · funding coverage
Angle Health funding, valuation and investors
AI-native healthcare benefits platform for small businesses — level-funded plans with broker quoting and care navigation.
Verified company research · funding, investors and latest developments
Keep track of Angle Health
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series C
$200M (+ $400M tender) · September 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$134M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · San Francisco, CA, USA
Investors in latest funding
Lead: Vitruvian Partners
Other: Town Hall Ventures , Blumberg Capital , Portage Ventures , PruVen Capital , Y Combinator
Overview
Angle Health (not Angle Protocol / angle.money) is a San Francisco healthcare benefits company that sells level-funded health plans and AI-native plan administration to small and midsize employers. Founded by ex-Palantir engineers including CEO Ty Wang, it is a Y Combinator Winter 2020 alum.
On September 18, 2026 the company announced a $600 million equity financing package at a $2.7 billion valuation: $200 million Series C led by Vitruvian Partners plus a $400 million tender offer for employee and early-investor liquidity. Town Hall Ventures joined; Blumberg Capital, Portage Ventures, PruVen Capital, and Y Combinator returned. Closing is expected later in September.
Company claims include 120% YoY growth, median renewal increases of 5–7% vs ~18% SMB market median (Morgan Health / company), plans in 47 states, and nearly $1 billion in annualized premium-equivalents. The Wall Street Journal reported the secondary priced near $2.5B — below the primary mark. Do not confuse with the DeFi stablecoin protocol at /startup/angle.
Why Angle Health is interesting
September 18, 2026: Vitruvian led a $200M Series C (plus $400M tender) at $2.7B for a YC W20 company that says it serves 5,000+ employers, ~$1B premium-equivalents, and four consecutive quarters of EBITDA and GAAP profitability — rare growth software economics in SMB health insurance.
Product & use cases
Benefit Builder and Quote-to-Card platforms let brokers generate underwritten quotes from a census, customize level-funded plans, and issue coverage. AI navigation and condition-specific care pathways sit on top of plan administration for employers with as few as two employees (state-dependent).
- SMB employers seeking level-funded plans between fully insured and self-funded
- Brokers needing fast underwritten quotes and plan customization
- Employees needing AI-assisted navigation into lower-cost care pathways
Key facts
- Sep 18, 2026: $200M Series C + $400M tender at $2.7B (company); close expected later in September
- Vitruvian led; Town Hall new; Blumberg, Portage, PruVen, YC returning
- Company: 5,000+ employers, ~$1B premium-equivalents, 4 quarters EBITDA + GAAP net income
- WSJ: secondary near $2.5B — do not treat tender as primary at $2.7B
Funding history (newest first)
Series C
2026-09 $200M (+ $400M tender)- Vitruvian Partners (lead)
- Town Hall Ventures (participant)
- Blumberg Capital (participant)
- Portage Ventures (participant)
- PruVen Capital (participant)
- Y Combinator (participant)
Source: Read source · anglehealth.com
Competitive landscape
Edge: Company-disclosed profitability plus renewal pricing below market benchmarks is the diligence hook versus pure ICHRA or broker-tool startups that lack an insurance P&L.
Angle sells an insurance product plus admin software. Thatch sells ICHRA tooling. Do not treat a $2.7B mark as interchangeable with ICHRA platforms that disclose employer counts without premium-equivalents.
-
Thatch Health adjacent
ICHRA / individual-budget benefits — different product from Angle’s level-funded group plans. See /startup/thatch-health.
-
Traditional carriers / TPAs incumbent
Fully insured group plans and legacy admin stacks Angle positions against.
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Angle Health
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.